Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale

Author:

Viana Kelvinson1ORCID,Zarpelon Luis1ORCID,Leandro Andre2,Terencio Maria1ORCID,Lopes Renata2ORCID,Martins Caroline2,Silva Isaak2,Sibim Alessandra1,Marques Fábio3,da Silva Rafael3ORCID,Rivas Açucena1ORCID,Souza Adrieli1ORCID,dos-Santos Angelo1ORCID,Torres Sara1ORCID,Garcia Maria1,Giunchetti Rodolfo4,Chiba-de-Castro Wagner1ORCID

Affiliation:

1. Universidade Federal da Integração Latino-Americana, Foz do Iguaçu, Brazil

2. Centro de Controle de Zoonoses de Foz do Iguaçu, Brazil

3. Fundação Municipal de Saúde de Foz do Iguaçu, Brazil

4. Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide as a severe pandemic, and a significant portion of the infected population may remain asymptomatic. Given this, five surveys were carried out between May and September 2020 with a total of 3585 volunteers in the municipality of Foz do Iguaçu, State of Paraná, a triple border region between Brazil/Argentina/Paraguay. Five months after the first infection, volunteers were re-analysed for the production of IgG anti-Spike and anti-RBD-Spike, in addition to analyses of cellular immunity. Seroconversion rates ranged from 4.4 % to a peak of 37.21 % followed by a reduction in seroconversion to 21.1 % in September, indicating that 25 % of the population lost their circulating anti-SARS-CoV-2 antibodies 3 months after infection. Analyses after 5 months of infection showed that only 17.2 % of people still had anti-RBD-Spike antibodies, however, most volunteers had some degree of cellular immune response. The strategy of letting people become naturally infected with SARS-CoV-2 to achieve herd immunity is flawed, and the first contact with the virus may not generate enough immunogenic stimulus to prevent a possible second infection.

Funder

Ministério da Educação

Publisher

Microbiology Society

Subject

Virology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3